期刊文献+

脂质体紫杉醇单药或联合卡培他滨在晚期乳腺癌中的效果分析 被引量:1

下载PDF
导出
摘要 目的:研究脂质体紫杉醇单药或联合卡培他滨在晚期乳腺癌中的效果。方法:选择84例晚期乳腺癌患者临床资料,根据治疗方法的不同分为对照组和观察组,对照组42例采用脂质体紫杉醇单药治疗,观察组42例采用脂质体紫杉醇联合卡培他滨治疗。将两组晚期乳腺癌患者的治疗效果、不良反应发生率进行比对。结果:观察组晚期乳腺癌患者的疾病总控制率高于对照组,差异具有统计学意义(P<0.05);观察组患者的消化道反应、血液毒性、肝肾功能异常等不良反应发生率高于对照组,但差异无统计学意义(P>0.05)。结论:脂质体紫杉醇联合卡培他滨治疗晚期乳腺癌效果比脂质体紫杉醇单药治疗更加优越。
作者 董雪茹
出处 《山西卫生健康职业学院学报》 CAS 2019年第5期39-40,共2页 Journal of shanxi health vocational college
  • 相关文献

参考文献6

二级参考文献76

  • 1Hahn S Y,Ko E Y,Han B K,et al.Role of diffusionweighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy[J].European Journal of Radiology,2014,83(2):283-288. 被引量:1
  • 2Buchbender C,Kuemmel S,Hoffmann O,et al.FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients:Initial results[J].Acta Radiologica,2012,53(6):628-636. 被引量:1
  • 3潘艳霞,徐峰,张志红,等.紫杉醇脂质体与紫杉醇联合表阿霉素在乳腺癌新辅助化疗中的疗效对比[J].医学信息,2015,28(8):330. 被引量:1
  • 4Rolfe M I,Mengersen K L,Vearncombe K J,et al.Bayesian estimation of extent of recovery for aspects of verbal memory in women undergoing adjuvant chemotherapy treatment for breast cancer[J].Journal of the Royal Statistical Society:Series C(Applied Statistics),2011,60(5):655-674. 被引量:1
  • 5Berrada N , Delaloge S, Andre F. Treatment of triple-negative metastaticbreast cancer:toward individualized targeted treatments or chemosensitiza-tion?[J]. Ann Oncol,2010,21 Suppl 7:vii30-vii35. 被引量:1
  • 6Kim HR, Jung KH, Im SA, et al. Multicentre phase II trial of bevacizumabcombined with docetaxel-carboplatin for the neoadjuvant treatment oftriple-negative breast cancer (KCSG BR-0905) [J]. Ann Oncol,2013,24(6):1485-1490. 被引量:1
  • 7Silver DP , Richardson AL, Eklund AC , et al. Efficacy of neoadjuvantCisplatin in triple-negative breast cancer[J]. J Clin Oncol,2010,28(7):1145-1153. 被引量:1
  • 8Venkitaraman R. Triple - negative / basal - like breast cancer : clinical,pathologicand molecular features[J]. Expert Rev Anticancer Ther,2010,10(2):199-207. 被引量:1
  • 9Isakoff SJ, Mayer EL, He L, et, al. TBCRC009 : a Multicenter phase I clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015,33 (17) : 1902-1909. 被引量:1
  • 10O'Shaughnessy J, Schwartzberg L, Danso MA , et al. Phase III study ofiniparib plus gemcitabine and carboplatin versus gemcitabine andcarboplatin in patients with metastatic triple-negative breast cancer [Jj.J Clin Oncol, 2014,32( 34) : 3840-3847. 被引量:1

共引文献34

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部